

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities described herein have not been and will not be registered under the U.S. Securities Act. There will be no public offering of securities in the United States of America or any jurisdiction other than Hong Kong.

Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

FOSUN PHARMA
复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

FOSUN 复星

復星國際有限公司

FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 00656)

**JOINT ANNOUNCEMENT
PROPOSED SPIN-OFF AND SEPARATE LISTING OF
SHANGHAI HENLIUS
ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE
PUBLICATION OF THE UPDATED APPLICATION PROOF**

1. INTRODUCTION

The boards of directors of Fosun Pharma and Fosun International refer to the announcements made by Fosun Pharma and Fosun International dated 27 September 2018 and 13 December 2018 (the “**Announcements**”) relating to the Proposed Spin-off and Listing. Unless the context otherwise requires, terms defined in the Announcements shall have the same meanings as those used in this announcement.

2. LISTING APPLICATION AND APPLICATION PROOF

Fosun Pharma and Fosun International were informed that on 5 July 2019, Shanghai Henlius submitted, through its joint sponsors, an updated listing application (Form A1) to the Hong Kong Stock Exchange to apply for the listing of, and permission to deal in, the Shanghai Henlius H Shares on the Main Board of the Hong Kong Stock Exchange.

A redacted form of the updated application proof of the prospectus of Shanghai Henlius (the “**Application Proof**”) is expected to be available for viewing and downloading on the website of the Hong Kong Stock Exchange (www.hkexnews.hk) from 5 July 2019. The Application Proof contains, among other things, certain business and financial information relating to Shanghai Henlius.

Shareholders and potential investors of Fosun Pharma and/or Fosun International should be aware that the Application Proof is in draft form and the information contained therein is subject to change which may be material. Each of Fosun Pharma and Fosun International shall not have any obligation or liability whatsoever in relation to the contents of the Application Proof.

As disclosed in the Announcements, the size of the proposed offering of Shanghai Henlius H Shares will be no more than 15% of the enlarged total share capital of Shanghai Henlius. In addition, it is proposed that the underwriter(s) will be granted an over-allotment option of no more than 15% of the number of Shanghai Henlius H Shares initially to be offered. Following the Proposed Spin-off and Listing, Shanghai Henlius will remain as a subsidiary of Fosun Pharma.

3. GENERAL

As it is expected that the highest of the applicable percentage ratios (as defined in the Listing Rules) in respect of the Proposed Spin-off and Listing shall be less than 5%, the Proposed Spin-off and Listing, if it proceeds, will not constitute a notifiable transaction for each of Fosun Pharma and Fosun International under the Listing Rules.

Shareholders and potential investors of Fosun Pharma and/or Fosun International are advised to note that the Proposed Spin-off and Listing is subject to, among other things, the approvals of the Hong Kong Stock Exchange and the CSRC, the final decision of the board of directors from Shanghai Henlius, market conditions and other factors. Accordingly, shareholders and potential investors of Fosun Pharma and/or Fosun International should be aware that there is no assurance that the Proposed Spin-off and Listing will take place or as to when it may take place. Shareholders and potential investors of Fosun Pharma and/or Fosun International should therefore exercise caution when dealing in the securities of Fosun Pharma and/or Fosun International. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

Further announcements will be made by Fosun Pharma and/or Fosun International in respect of the Proposed Spin-off and Listing (including details relating to the Assured Entitlement) as and when appropriate.

By order of the board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

By order of the board
Fosun International Limited
Guo Guangchang
Chairman

5 July 2019

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao, Mr. Wang Can and Mr. Gong Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.

* For identification purposes only